Brochure: Fast and simple plasma protein binding studies
Posted: 17 February 2021 | Merck | No comments yet
Supel™ BioSPME 96-Pin Devices vastly outperform current sample preparation techniques for plasma protein binding studies and free fraction analyses.
Based on solid phase microextraction technology, the Supel™ BioSPME 96-Pin Devices are 3x faster than rapid equilibrium dialysis workflows at similar levels of data accuracy and precision, they remove all phospholipids, deliver reproducible results across batches and each 96-sample device, and allow both manual and automated workflows.
An application note features the results of a detailed comparison with the rapid equilibrium dialysis technique.
Related content from this organisation
- Antibody-immunotherapy treatment shows benefit in serious endometrial cancer
- First-in-class biologic approved for rare lung disease
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Pharmaceutical suspension market to witness accelerated growth
- Immunotherapy drug achieves trial-first in fifty years
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, QA/QC, Regulation & Legislation, Research & Development (R&D)
